Market Research Logo

Generics in Turkey

Generics in Turkey

Summary

Generics in Turkey industry profile provides top-line qualitative and quantitative summary information including: market size (value and volume 2013-17, and forecast to 2022). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market.

Synopsis

Essential resource for top-line data and analysis covering the Turkey generics market. Includes market size data, textual and graphical analysis of market growth trends, leading companies and macroeconomic information.

Key Highlights

  • For the purposes of this profile, a generic drug is defined as a copy of an ethical (prescription) drug formerly protected by patents that have now expired. Both unbranded generics and all branded generics are included. However, off-patent drugs that continue to be offered by the original manufacturer under the original name, and which form part of the 'generic-eligible' market, are not included.
  • The Turkish generics market had total revenues of $2.2bn in 2017, representing a compound annual growth rate (CAGR) of 16.4% between 2013 and 2017.
  • Market consumption volume increased with a CAGR of 1.7% between 2013 and 2017, to reach a total of 58.7% in 2017.
  • Despite being launched in 2003, the Health Transformation Program was intended to improve hospital infrastructure and utilize the latest technology. However, in late 2014, the first PPP project financially closed after an investment from Siemens.
Scope
  • Save time carrying out entry-level research by identifying the size, growth, and leading players in the generics market in Turkey
  • Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the generics market in Turkey
  • Leading company profiles reveal details of key generics market players’ global operations and financial performance
  • Add weight to presentations and pitches by understanding the future growth prospects of the Turkey generics market with five year forecasts by both value and volume
Reasons to buy
  • What was the size of the Turkey generics market by value in 2017?
  • What will be the size of the Turkey generics market in 2022?
  • What factors are affecting the strength of competition in the Turkey generics market?
  • How has the market performed over the last five years?
  • How large is Turkey’s generics market in relation to its regional counterparts?


Executive Summary
Market value
Market value forecast
Market volume
Market volume forecast
Geography segmentation
Market rivalry
Market Overview
Market definition
Market analysis
Market Data
Market value
Market volume
Market Segmentation
Geography segmentation
Market Outlook
Market value forecast
Market volume forecast
Five Forces Analysis
Summary
Buyer power
Supplier power
New entrants
Threat of substitutes
Degree of rivalry
Leading Companies
Abdi Ibrahim Ilac Sanayi ve Ticaret AS
Deva Holding AS
Nobel Pharmaceuticals
Novartis AG
Macroeconomic Indicators
Country data
Methodology
Industry associations
Related MarketLine research
Appendix
About MarketLine
List of Tables
Table 1: Turkey generics market value: $ million, 2013-17
Table 2: Turkey generics market volume: % of total pharma, 2013-17
Table 3: Turkey generics market geography segmentation: $ million, 2017
Table 4: Turkey generics market value forecast: $ million, 2017-22
Table 5: Turkey generics market volume forecast: % of total pharma, 2017-22
Table 6: Abdi Ibrahim Ilac Sanayi ve Ticaret AS: key facts
Table 7: Deva Holding AS: key facts
Table 8: Deva Holding AS: key financials ($)
Table 9: Deva Holding AS: key financials (TL)
Table 10: Deva Holding AS: key financial ratios
Table 11: Nobel Pharmaceuticals: key facts
Table 12: Novartis AG: key facts
Table 13: Novartis AG: key financials ($)
Table 14: Novartis AG: key financial ratios
Table 15: Turkey size of population (million), 2013-17
Table 16: Turkey gdp (constant 2005 prices, $ billion), 2013-17
Table 17: Turkey gdp (current prices, $ billion), 2013-17
Table 18: Turkey inflation, 2013-17
Table 19: Turkey consumer price index (absolute), 2013-17
Table 20: Turkey exchange rate, 2013-17
List of Figures
Figure 1: Turkey generics market value: $ million, 2013-17
Figure 2: Turkey generics market volume: % of total pharma, 2013-17
Figure 3: Turkey generics market geography segmentation: % share, by value, 2017
Figure 4: Turkey generics market value forecast: $ million, 2017-22
Figure 5: Turkey generics market volume forecast: % of total pharma, 2017-22
Figure 6: Forces driving competition in the generics market in Turkey, 2017
Figure 7: Drivers of buyer power in the generics market in Turkey, 2017
Figure 8: Drivers of supplier power in the generics market in Turkey, 2017
Figure 9: Factors influencing the likelihood of new entrants in the generics market in Turkey, 2017
Figure 10: Factors influencing the threat of substitutes in the generics market in Turkey, 2017
Figure 11: Drivers of degree of rivalry in the generics market in Turkey, 2017
Figure 12: Deva Holding AS: revenues & profitability
Figure 13: Deva Holding AS: assets & liabilities
Figure 14: Novartis AG: revenues & profitability
Figure 15: Novartis AG: assets & liabilities

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook